Fosrenol 1000 mg Tuggtablett

国: スウェーデン

言語: スウェーデン語

ソース: Läkemedelsverket (Medical Products Agency)

有効成分:

lantan(III)karbonattetrahydrat

から入手可能:

Paranova Läkemedel AB

ATCコード:

V03AE03

INN（国際名）:

lanthanum(III)karbonattetrahydrat

投薬量:

1000 mg

医薬品形態:

Tuggtablett

構図:

lantan(III)karbonattetrahydrat 1908 mg Aktiv substans; dextrat, hydratiserat Hjälpämne

処方タイプ:

Receptbelagt

製品概要:

Förpacknings: Burk, 90 (6 x 15) tabletter

認証ステータス:

Avregistrerad

承認日:

2017-07-12

情報リーフレット

1
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
FOSRENOL 250 MG CHEWABLE TABLETS
FOSRENOL 500 MG CHEWABLE TABLETS
FOSRENOL 750 MG CHEWABLE TABLETS
FOSRENOL 1000 MG CHEWABLE TABLETS
lanthanum
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Fosrenol is and what it is used for
2.
What you need to know before you take Fosrenol
3.
How to take Fosrenol
4.
Possible side effects
5.
How to store Fosrenol
6.
Contents of the pack and other information
1.
WHAT FOSRENOL IS AND WHAT IT IS USED FOR
Fosrenol is used to lower the phosphate level in the blood of adult
patients with chronic kidney
disease.
Patients who have kidneys that do not work properly are not able to
control the level of phosphate in
the blood. The amount of phosphate in the blood then rises (your
doctor may call this
hyperphosphataemia).
Fosrenol is a medicine which reduces the body's absorption of
phosphate from food by binding with it
in your digestive tract. Phosphate which has bonded to Fosrenol cannot
be absorbed through the
intestinal wall.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE FOSRENOL
DO NOT TAKE FOSRENOL
-
if you are allergic to lanthanum carbonate hydrate or any of the other
ingredients of this
medicine (listed in section 6)
-
if you have too little phosphate in your blood (hypophosphataemia).
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Fosrenol if you know
that you have, or have had, any
of the following:
-
stomach or intestinal cancer
-
inflammatory bowel disease including ulcerative colitis or Cro

製品の特徴

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Fosrenol 250 mg chewable tablets.
Fosrenol 500 mg chewable tablets.
Fosrenol 750 mg chewable tablets.
Fosrenol 1000 mg chewable tablets.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains lanthanum carbonate hydrate
corresponding to 250 mg,500 mg, 750 mg
lanthanum.
Excipient with known effect
250 mg: Chewable tablets also contain on average 533 mg of dextrates,
containing glucose.
500 mg: Chewable tablets also contain on average 1066 mg of dextrates,
containing glucose.
750 mg: Chewable tablets also contain on average 1599 mg of dextrates,
containing glucose.
1000 mg: Chewable tablets also contain on average 2132 mg of
dextrates, containing glucose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet.
250 mg: White, round, 13-mm, bevelled-edge flat tablets debossed with
‘S405/250’ on one side.
500 mg: White, round, 18-mm, bevelled-edge flat tablets debossed with
‘S405/500’ on one side.
750 mg: White, round, 20-mm, bevelled-edge flat tablets debossed with
‘S405/750’ on one side.
1000 mg: White, round, 22-mm, bevelled-edge flat tablets debossed with
‘S405/1000’ on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Fosrenol is indicated in adult patients as a phosphate binding agent
for use in the control of
hyperphosphataemia in chronic renal failure patients on haemodialysis
or continuous ambulatory
peritoneal dialysis (CAPD). Fosrenol is also indicated in adult
patients with chronic kidney disease not
on dialysis with serum phosphate levels

1.78 mmol/L in whom a low phosphate diet alone is
insufficient to control serum phosphate levels.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Fosrenol is for oral administration.
The tablets must be chewed completely and not swallowed whole. To aid
with chewing the tablets
may be crushed. Where Fosrenol oral powder is available, it can
replace chewable tablets in patients
who have difficulty chewing the tablets (see sectio